04.12.23 -- Core Outcome Sets: What Are They & Why Are They Needed?

Decentralized clinical trials and all their elements are touted as flexible options for patients. But what about the sites carrying them out? Jimmy Bechtel of the Society for Clinical Research Sites (SCRS) says sites are looking for clarity and consistency when it comes to the tech being thrust upon them by sponsors and CROs.

Discover how one mobile research services and clinical trials provider addresses CRO and sponsor concerns associated with decentralized clinical trials.

Unearth the truth and see how decentralized clinical trials are a fast-growing resource for sponsors to increase patient recruitment and retention.

The introduction of novel solutions to facilitate adherence can support decentralized trials and mitigate potential concerns surrounding reduced patient-physician touchpoints.

Explore the current DCT landscape and its evolution, as well as the key advantages of incorporating decentralized attributes and how barriers to their inclusion can be overcome.

Clinical ink offers a best-in-class analytics platform to support the development and evaluation of digital biomarkers in clinical trials.

A single trial provides just a snapshot of evidence. Many trials provide a summative account of how effective an intervention can be. When the selected outcomes are different from trial to trial, it becomes much more challenging to reach a conclusion. Stuart Nicholls of the Ottawa Hospital Research Institute advocates core outcome sets as the remedy.

How did we arrive at neurological cell therapy solutions? Dr. Ole Isacson explores the stem cell steppingstones — from blood transfusions to Parkinson’s disease treatments.

Better manage a supply chain through IRT with self-service tools, actionable insights, and best practices for supply forecasting and overstock management.

Elevate your knowledge of clinical trials and the trial master file by exploring three critical topics with industry experts Rob Jones and Jacki Petty.

Get an overview of the critical planning activities and milestones in the drug development process and which important regulatory considerations should be taken at each stage.

Learn why it’s critical to understand the analytical validity and technical limitations of circulating tumor DNA sequencing in precision oncology.

Learn how experts apply imaging science and operational expertise to identify and manage the inherent risks to capturing complete and high-quality central review data of study endpoints.

For small or large molecules, simple or complex trials, Altasciences has the expertise, purpose-built Phase 1 facilities, and seamless processes to deliver quality with speed and ease.

Read for a closer look at the findings in ISR's Cell & Gene Therapies Market Outlook report, which offers some insight into the expanding cell and gene therapy field for innovators and manufacturers.